In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio

Published:2015-09 Issue:3 Volume:116 Page:486-494
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Gani Cihan,Coackley Carla,Kumareswaran Ramya,Schütze Christina,Krause Mechthild,Zafarana Gaetano,Bristow Robert G.

Funder

Terry Fox Foundation Program Project

Prostate Cancer Canada

Canadian Cancer Society Research Institute

Canadian Foundation for Innovation

Ontario Ministry of Health and Long-Term Care

Deutsche Krebshilfe

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference40 articles.

1. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer;Kuban;Int J Radiat Oncol Biol Phys,2008

2. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer;Zelefsky;J Urol,2006

3. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study;Bolla;Lancet Oncol,2010

4. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials;Viani;Int J Radiat Oncol Biol Phys,2009

5. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer;Milosevic;Clin Cancer Res,2012

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors;DNA Repair;2024-07

2. Mechanisms of traditional Chinese medicine overcoming of radiotherapy resistance in breast cancer;Frontiers in Oncology;2024-06-27

3. Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal;2024-06-18

4. Patents on PARP-1 Inhibitors for the Management of Cancer from 2017-2023;Recent Patents on Anti-Cancer Drug Discovery;2024-06-13

5. Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency;International Review of Cell and Molecular Biology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3